News | December 19, 2024
Cipla launches India's first inhalable insulin ‘Afrezza’
Afrezza, developed by MannKind Corporation in the USA, offers a needle-free, rapid-acting insulin option for diabetes management
Afrezza, developed by MannKind Corporation in the USA, offers a needle-free, rapid-acting insulin option for diabetes management
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
A 40 minute daily Yoga routine, incorporating select asanas and pranayama, along with standard lifestyle interventions, can reduce the risk of developing diabetes by approximately 40%
Harnessing advanced data analysis for early detection, prevention and better outcomes
The trademark rights for these brands will be transferred to Lupin by March next year.
Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list
Aims to become India’s leading cancer testing company
Reaffirms Lupin’s commitment to sustainable resource management
She will be responsible in this role for Finance & Controlling, HR Services and IT Management at Romaco Holding
The product will be marketed by Dr. Reddy's
Subscribe To Our Newsletter & Stay Updated
